This peer-reviewed study published in Pharmaceutics evaluates the endocrine and metabolic effects of a natural carob pod–derived syrup containing glucose, fructose, and approximately 3% D-Pinitol (Innosweet®), positioning it as a novel functional sweetener.
In healthy human volunteers, Innosweet® produced shorter and less persistent glucose excursions compared to glucose, alongside a significantly reduced insulin response, while maintaining a comparable glycemic index. Importantly, the syrup increased the glucagon/insulin ratio, supporting a more insulin-efficient metabolic response rather than excessive insulin secretion.
Preclinical studies confirmed these findings, showing improved glucose handling after repeated intake, reduced hepatic fat accumulation, decreased liver glycogen, enhanced fatty acid oxidation, and no evidence of liver or kidney toxicity. At the molecular level, Innosweet® modulated insulin signaling pathways and reduced tau hyperphosphorylation in the hippocampus, linking metabolic regulation with potential neuroprotective effects.
Overall, this study demonstrates that Innosweet® preserves sweetness and caloric value while actively supporting metabolic balance, positioning it as a differentiated alternative to conventional sugars and non-nutritive sweeteners.